Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to -$426000.0.

  • Kezar Life Sciences' Change in Accured Expenses fell 12841.89% to -$426000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.3 million, marking a year-over-year decrease of 117885.8%. This contributed to the annual value of -$3.1 million for FY2024, which is 14956.67% down from last year.
  • Latest data reveals that Kezar Life Sciences reported Change in Accured Expenses of -$426000.0 as of Q3 2025, which was down 12841.89% from -$2.7 million recorded in Q2 2025.
  • Kezar Life Sciences' 5-year Change in Accured Expenses high stood at $2.9 million for Q3 2023, and its period low was -$3.6 million during Q1 2025.
  • Its 5-year average for Change in Accured Expenses is -$27157.9, with a median of $200000.0 in 2022.
  • As far as peak fluctuations go, Kezar Life Sciences' Change in Accured Expenses soared by 37950.0% in 2023, and later tumbled by 270927.84% in 2025.
  • Kezar Life Sciences' Change in Accured Expenses (Quarter) stood at $60000.0 in 2021, then skyrocketed by 233.33% to $200000.0 in 2022, then soared by 379.5% to $959000.0 in 2023, then plummeted by 260.48% to -$1.5 million in 2024, then soared by 72.32% to -$426000.0 in 2025.
  • Its Change in Accured Expenses was -$426000.0 in Q3 2025, compared to -$2.7 million in Q2 2025 and -$3.6 million in Q1 2025.